Evolocumab

7 trials 2 recruiting CCardiology

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

3 Completed trials

6 Sponsors

22 Countries

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 1 Phase IV: 5

Oversight events:

2 serious breaches 1 corrective measure across 2 trials

View oversight register →

Sponsors using this IMP

Amgen Inc. 2 Assistance Publique Hopitaux De Paris 1 Azienda Ospedaliera Ordine Mauriziano Di Torino 1 Centre Hospitalier Universitaire Grenoble Alpes 1 Karolinska University Hospital 1 Medical University Of Vienna 1

All trials

7 total

Studies to gain insight how the drugs PCSK9-inhibitors and statins affect cholesterol and bile acid metabolism Pending

2023-505726-34-02 Phase IV 1 country Karolinska University Hospital
CARotid plaqUe StabilizatiOn and regression with evolocumab Pending

2024-518566-27-00 Phase IV 1 country Azienda Ospedaliera Ordine Mauriziano Di Torino
AMUNDSEN - Acute Myocardial infarction Upbound to percutaneous coronary intervention, immediately (STEMI) or in the Next three Days (NSTEMI)… Recruiting

2024-518195-31-00 Phase IV 5 countries Assistance Publique Hopitaux De Paris
The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and relate… Recruiting

2024-516967-10-00 Phase IV 1 country Medical University Of Vienna
EVOLVE-MI Ended

2023-509268-26-00 Phase IV 1 country Amgen Inc.
Effect of impact of PCSK9 inhibitor on coronary microvascular dysfunction in patients with atherosclerotic cardiovascular disease needing co… Ended

2024-519012-14-00 Phase II 1 country Centre Hospitalier Universitaire Grenoble Alpes
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Phase III 22 countries Amgen Inc.

Showing 1–7 of 7 trials

← All drugs A–Z